Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis.
about
Construction of an miRNA-regulated drug-pathway network reveals drug repurposing candidates for myasthenia gravis.Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis.Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs.Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world.Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program.Evolution of Patient-Reported Outcomes and Their Role in Multiple Sclerosis Clinical Trials.
P2860
Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Alemtuzumab improves quality-o ...... -remitting multiple sclerosis.
@en
Alemtuzumab improves quality-o ...... -remitting multiple sclerosis.
@nl
type
label
Alemtuzumab improves quality-o ...... -remitting multiple sclerosis.
@en
Alemtuzumab improves quality-o ...... -remitting multiple sclerosis.
@nl
prefLabel
Alemtuzumab improves quality-o ...... -remitting multiple sclerosis.
@en
Alemtuzumab improves quality-o ...... -remitting multiple sclerosis.
@nl
P2093
P2860
P356
P1476
Alemtuzumab improves quality-o ...... -remitting multiple sclerosis.
@en
P2093
CARE-MS I and II Investigators
David H Margolin
Eva Havrdova
Heidi Crayton
Mariko Kita
Rafael Arroyo González
Stephen L Lake
P2860
P304
P356
10.1177/1352458516677589
P577
2016-11-24T00:00:00Z